3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
14
Neoplasms
9
Advanced Breast Cancer
6
Endometrial Neoplasms
5
Recurrence
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Lobular
3
Carcinoma, Ductal, Breast
3
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Osteoporosis
2
Neoplasms by Site
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Breast Neoplasms, Male
2
Breast Diseases
2
Bone Diseases, Metabolic
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Osteitis Deformans
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
exemestane
4
entinostat
4
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
pembrolizumab
1
ipatasertib
1
figitumumab
1
elacestrant
1
dactolisib
1
atezolizumab
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Lapatinib
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Diseases
×
Letrozole
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled